Experimmune

Experimmune is no longer in operation. Whether for contract purposes or third party validation, Experimmune offers full-scale laboratory support for all major phases of a customer’s immunological research and development. Since our expertise falls within the areas of immunodiagnostics and immunotherapeutics, we support services for pre-clinical animal models and human specimens that include but are not limited to: assay development, antigen discovery (B and T cell epitope characterization), and humoral/cell-mediated analysis. At Experimmune, we specifically tailor our methods to the goals of its customers. In addition to immunodiagnostic and immunotherapeutic development, we are able to offer a wide range of services. These services include pre-clinical in vitro and in vivo efficacy models for oncology as well as pharmacokinetic and immunogenicity studies utilizing your drug or drug carrier. Experimmune provides high-quality monoclonal and polyclonal antibody services for research purposes. We offer competitive packages for generating antibodies to protein and peptide targets against a range of species including mice and humans. Ultimately, our team will deliver exceptional one-on-one guidance in meeting the antibody needs of its customers.

Celexion LLC

Celexion is a protein discovery and engineering company based in Cambridge, Massachusetts. We use our proprietary SECANTâ„¢ platform to display complex proteins on the surface of eukaryotic cells. This platform, combined with state-of-the-art library construction and screening capabilities, allows us to rapidly discover and engineer new proteins for applications in therapeutics, diagnostics, and life science tools.

Avacta Analytical

Avacta Analytical provided analytical contract research and innovative instrumentation to the biopharmaceutical sector before the sale of its business in 2015.

Antoon Santegoeds

Website of the past company as the current company has no business website.

BRT Blood Reprogramming Technologies Lda

Blood Reprogramming Technologies (BRT) was founded in March 2017 as a spin-off from the Center for Neuroscience and Cell Biology, University of Coimbra in Portugal. BRT is specialized in R&D and in the use of direct cell reprogramming technologies to generate autologous blood products with clinical application for regenerative medicine. We are developing blood products focusing on hematopoietic stem cell (HSC) transplantation. We aim to serve patients by translating scientific discoveries into products for blood regeneration. Our mission is to improve patients’ health by increasing the therapeutic efficacy of currently performed treatments for blood-based diseases. At the same time we aim to reduce the incidence of adverse side effects that represent a huge economic burden for healthcare systems.